ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Cardiac monitoring in adolescent and young adult cancer patients treated with anthracyclines: a longitudinal descriptive study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe quantified the real-world prevalence of echocardiographic monitoring and identified factors associated with baseline echocardiography among adolescent and young adult (AYA; 15-39 years) cancer patients treated with anthracyclines in Japan.
methodsWe performed a descriptive study using a Japanese health insurance claims database in patients initiating anthracycline chemotherapy between April 2012 and July 2020. We calculated the proportion undergoing echocardiography within 180 days before therapy (baseline); before the second, fourth, and sixth cycles; at any time during therapy; and within 1 year after completion. Risk ratios for receipt of baseline echocardiography by patient and institutional characteristics were estimated using univariable modified Poisson regression.
resultsAmong 1459 AYA patients (mean age, 31.7 years; 65.1% female), 60.4% underwent baseline echocardiography. Utilization declined to 8.2%, 11.4%, and 20.9% before the second, fourth, and sixth cycles, respectively; was 13.7% at any time during therapy; and 41.0% within 1-year post-therapy. Baseline echocardiography was more common for age 15-19 and 20-29 years (vs. ≥ 30-39 years) and males; lymphoma, leukemia, bone sarcoma, and pre-existing heart failure; and chemotherapy at a designated cancer hospital. Likelihood was lower for breast cancer; clinic (vs. university hospital); and epirubicin, idarubicin, or pirarubicin (vs. doxorubicin).
conclusionEchocardiographic monitoring before, during, and after anthracycline therapy in Japanese AYA patients is suboptimal, with marked disparities by age, sex, cancer type, anthracycline agent, and treatment setting. Targeted quality-improvement initiatives and harmonized risk-stratified monitoring pathways are needed to prevent unrecognized anthracycline-related cardiomyopathy in this vulnerable population.
Indexed as
Identifiers
42189326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.